Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06789172 |
| Title | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients with Solid Tumors (INVOKE) |
| Acronym | INVOKE |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Epkin |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Precision NextGen Oncology and Research Center | RECRUITING | Beverly Hills | California | 90212 | United States | Details |
| Sarcoma Oncology Center | RECRUITING | Santa Monica | California | 90403 | United States | Details |